Cystic Fibrosis Therapeutics.

The article discusses candidate treatments for cystic fibrosis (CF) lung disease included in the Cystic Fibrosis Foundation Therapeutics Pipeline in the U.S. A new preparation of inhaled tobramycin (TOBI) called TOBI inhaled powder (TIP) is being developed for treatment of infection. Antinflammatory treatments include N-acetylcysteine, docosahexenoic acid and sildenafil. Also tackled are drugs for mucus alteration/airway surface liquid modulation therapy and stem cell/gene therapy treatments.